

Novo Nordisk and Torrent expand insulin facility

12 December 2017 | News

Novo Nordisk believes that this expansion would enable the company to tap 5 million patients as compared to 3 million currently.



Novo Nordisk India and Torrent Pharmaceuticals recently announced the expansion of their insulin manufacturing facility at Torrent's Indrad factory.

The facility was inaugurated by Peter Taksoe-Jensen, Ambassador to India, Embassy of Denmark, Jinesh Shah, Executive Director, Torrent Pharmaceuticals, Frederik Kier, Senior Vice President, Region AAMEO, Novo Nordisk, and Melvin D'souza, Managing Director, Novo Nordisk India.

Novo Nordisk believes that this expansion would enable the company to tap 5 million patients as compared to 3 million currently.

Torrent Pharmaceuticals and Novo Nordisk began their partnership 25 years ago in 1992 with the manufacture and launch of insulin in 40 IU vials. In 2009, an integrated manufacturing and vial packaging plant was inaugurated.

As world leaders in diabetes care, Novo Nordisk partners with patients, policymakers, healthcare professionals and non-governmental organisations to address diabetes risk factors, thus ensuring that people with diabetes are diagnosed earlier.

Through the Changing Diabetes Barometer project, Novo Nordisk has partnered with seven state governments to create awareness about diabetes. As part of the project, till date, 700,000 people have been educated about diabetes and over 3700 doctors and paramedics have been trained through various capacity building programs